サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1363998

バイオ医薬品の世界市場：2023-2030年

Global Biopharmaceuticals Market 2023-2030

出版日
ページ情報
英文 250 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
バイオ医薬品の世界市場：2023-2030年
出版日: 2023年09月24日
発行: Orion Market Research
ページ情報: 英文 250 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のバイオ医薬品市場は、予測期間中（2023～2030年）にCAGR 7.2％で成長すると予測されています。がん・自己免疫疾患・糖尿病・心血管疾患などの慢性疾患は世界的に増加し続けています。バイオ医薬品の消費は世界的に伸びており、その一因は老化関連疾患や慢性疾患の治療薬に対するニーズの高まりにあります。複雑な疾患における創薬のための技術的進歩の採用が増加していることが、世界の市場の成長を支える主な要因です。世界保健機関（WHO）によると、2023年8月、HPV感染は世界全体のがんの約5.0%を引き起こし、毎年推定で女性625 600人、男性69 400人がHPV関連がんに罹患しています。ヒト免疫不全ウイルス（HIV）に感染している女性は、HIVに感染していない女性に比べ、子宮頸がんになる可能性が6倍高いです。子宮頸がんは、早期に発見され効果的に管理されれば治癒することが多いですが、進行した段階では治療の選択肢が限られます。市場関係者は慢性疾患治療薬のイントロダクション継続的に注力しています。例えば、2022年11月、Regeneron Pharmaceuticals, Inc.は、再発または転移性子宮頸がんでプラチナ製剤ベースの化学療法中または化学療法後に病勢進行した成人患者の治療薬としてLibtayo (R) (cemiplimab) を単剤療法として欧州委員会（EC）が承認したと発表しました。

セグメント別の見通し

ワクチン・サブセグメントが世界のバイオ医薬品市場で大きなシェアを占めると予想される

製品タイプの中では、ワクチンが世界のバイオ医薬品市場で大きなシェアを占めると予想されています。このセグメントの成長は、ワクチン開発プロセスにおけるナノテクノロジー、遺伝子ベースのアッセイ、次世代シークエンシング技術、遺伝子工学の統合の増加によるもので、新型ワクチンの革命的な可能性を高めると期待されています。核酸ワクチン、mRNAワクチン、ベクターワクチン、バイオマテリアルベースのワクチンは、既存技術の問題点を解決する可能性に基づくワクチン革命の最近の動向です。例えば、2023年9月、ファイザー社とバイオエヌテックSEは、両社のオミクロンXBB.1.5適応一価COVID-19ワクチンについて、米国FDAが12歳以上の個人を対象とした生物製剤追加承認申請を承認し、6カ月から11歳までの個人を対象とした緊急使用許可を与えたと発表しました。

地域別展望

世界のバイオ医薬品市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋（インド、中国、日本、韓国、その他アジア）、世界のその他の地域（中東とアフリカ、ラテンアメリカ）を含む地域別にさらに細分化されています。なかでもアジア太平洋地域は、医療施設が充実していること、複雑な疾患の根本的な原因を特定する高度な治療オプションが利用可能であること、治療成績が向上していること、患者ケアが充実していることなどから、世界全体で大きなシェアを占めると予想されます。

北米地域は世界のバイオ医薬品市場において著しいCAGRで成長する見込み

全地域の中で、北米地域は予測期間中にかなりのCAGRで成長すると予測されています。同地域の成長の背景には、疾病治療のためのバイオ医薬品の採用と入手の増加、疾病診断に対する意識の高まりがあります。経済が成長し、医療の提供や保険制度が拡大するにつれて、国産医薬品や輸入医薬品に対する需要が増加しました。2022年5月の欧州製薬団体連合会（EFPIA）によると、2021年の世界の医薬品売上高に占める北米の割合は49.1%であるのに対し、欧州は23.4%でした。新興国市場では、糖尿病や高血圧など、すでに経済力のある国々で流行している非感染性疾患（NCD）への対策が進む一方、後天性免疫不全症候群、マラリア、結核など、多くの新興国市場を苦しめている感染性疾患は依然として残っており、医薬品ニーズの多様化が進んでいます。世界人口の増加も医薬品消費に寄与しています。

高齢者人口の増加、がんや糖尿病などの慢性疾患の急増、世界のバイオ医薬品採用の増加など、さまざまな要因が市場成長の原動力となっています。さらに、バイオ医薬品企業間の戦略的提携の増加も、バイオ医薬品業界の成長を補完すると予想されています。市場の主要企業には、アッヴィ社、アストラゼネカ社、エフ・ホフマン・ラ・ロシュ社、メルク社、ファイザー社などが含まれます。

目次

第1章 レポート概要

  • 業界の現状分析と成長可能性の展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • AbbVie, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Johnson and Johnson Service, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Pfizer, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • F. Hoffman-La Roche, Ltd.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 世界のバイオ医薬品市場：製品タイプ別
    • モノクローナル抗体
    • 組み換え成長因子
    • 精製タンパク質
    • ワクチン
    • ホルモン
    • 遺伝子治療薬
    • その他（インターフェロン、合成免疫調節剤）
  • 世界のバイオ医薬品市場：サービス別
    • 臨床試験
    • 顧客独自の試験
    • 局法適合試験・局法横断型臨床試験
  • 世界のバイオ医薬品市場：用途別
    • 腫瘍
    • 炎症性疾患・感染症
    • 自己免疫疾患
    • 代謝疾患
    • 心血管疾患
    • 神経疾患
    • その他（ホルモン疾患）

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 世界のその他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第6章 企業プロファイル

  • AbbVie Inc.
  • Bayer AG
  • Abbott Laboratories
  • Allergan, Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • bioMerieux SA
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • GlaxoSmithKline PlcPharmaceuticals Ltd.
  • McKesson Corp.
  • Moderna, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Sanofi SA
  • Takeda Pharmaceutical Industries, Ltd.
  • Vertex Pharmaceuticals
図表

LIST OF TABLES

  • 1. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL RECOMBINANT GROWTH FACTORS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL PURIFIED PROTEINS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL HORMONE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL GENE THERAPIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL OTHER BIOPHARMACEUTICALS PRODUCTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 10. GLOBAL BIOPHARMACEUTICALS IN LABORATORY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL BIOPHARMACEUTICALS IN CUSTOMER PROPRIETARY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL BIOPHARMACEUTICALS IN COMPENDIAL AND MULTI COMPENDIAL LABORATORY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 14. GLOBAL BIOPHARMACEUTICALS FOR ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL BIOPHARMACEUTICALS FOR INFLAMMATORY AND INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL BIOPHARMACEUTICALS FOR AUTOIMMUNE DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL BIOPHARMACEUTICALS FOR METABOLIC DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL BIOPHARMACEUTICALS FOR CARDIOVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL BIOPHARMACEUTICALS FOR NEUROLOGICAL DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. GLOBAL BIOPHARMACEUTICALS FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 21. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 24. NORTH AMERICAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 25. NORTH AMERICAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 26. EUROPEAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 27. EUROPEAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 28. EUROPEAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 29. EUROPEAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 30. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 32. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 33. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 34. REST OF THE WORLD BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL BIOPHARMACEUTICALS MARKET SHARE BY TRANSACTION MODE, 2022 VS 2030 (%)
  • 2. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022 VS 2030 (%)
  • 3. GLOBAL MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL RECOMBINANT GROWTH FACTORS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL PURIFIED PROTEINS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL HORMONE MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL GENE THERAPIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL OTHER BIOPHARMACEUTICALS PRODUCTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022 VS 2030 (%)
  • 11. GLOBAL BIOPHARMACEUTICALS IN LABORATORY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL BIOPHARMACEUTICALS IN CUSTOMER PROPRIETARY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL BIOPHARMACEUTICALS IN COMPENDIAL AND MULTI COMPENDIAL LABORATORY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022 VS 2030 (%)
  • 15. GLOBAL BIOPHARMACEUTICALS FOR ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL BIOPHARMACEUTICALS FOR INFLAMMATORY AND INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL BIOPHARMACEUTICALS FOR AUTOIMMUNE DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 18. GLOBAL BIOPHARMACEUTICALS FOR METABOLIC DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 19. GLOBAL BIOPHARMACEUTICALS FOR CARDIOVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 20. GLOBAL BIOPHARMACEUTICALS FOR NEUROLOGICAL DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 21. GLOBAL BIOPHARMACEUTICALS FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 22. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 23. US BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. CANADA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. UK BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. FRANCE BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. GERMANY BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. ITALY BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. SPAIN BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF EUROPE BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. INDIA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. CHINA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. JAPAN BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 34. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 35. REST OF ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 36. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 37. MIDDLE EAST AND AFRICA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027725

Title: Global Biopharmaceuticals Market Size, Share & Trends Analysis Report by Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Vaccines, Hormones, Gene Therapies and Others), by Service (Laboratory Testing, Customer Proprietary Testing, Compendial and Multi Compendial Laboratory Testing), and by Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Cardiovascular Diseases, Neurological Diseases and Other),Forecast Period (2023-2030).

Global biopharmaceuticals market is anticipated to grow at a CAGR of 7.2 % during the forecast period (2023-2030). Chronic diseases such as cancer, autoimmune disorders, diabetes, and cardiovascular diseases continue to rise globally. Biopharmaceutical consumption globally growing, partly driven by a growing need for drugs to treat aging-related and chronic diseases. The growing adoption of technological advancement for drug discovery in complex diseases is the key factor supporting the growth of the market globally. According to the World Health Organization (WHO), in August 2023, HPV infection caused about 5.0% of all cancers globally, with an estimated 625 600 women and 69 400 men getting HPV-related cancer each year. Women living with human immunodeficiency virus (HIV) are six times more likely to develop cervical cancer compared to women without HIV. Cervical cancer is often curable when detected early and effectively managed, but treatment options are more limited in advanced stages. Market players are continuously focusing on the introduction of drugs for chronic diseases. For instance, in November 2022, Regeneron Pharmaceuticals, Inc. announced that the European Commission (EC) approved Libtayo® (cemiplimab) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Segmental Outlook

The global biopharmaceuticals market is segmented by product type, service, and application. Based on the product type, the market is sub-segmented into monoclonal antibodies, recombinant growth factors, purified proteins, vaccines, hormones, gene therapies, and others (interferon, synthetic immunomodulators). Based on the service, the market is sub-segmented into laboratory testing, customer proprietary testing, and compendial and multi-compendial laboratory testing. Further, based on application, the market is sub-segmented into oncology, inflammatory and infectious diseases, autoimmune disorders, metabolic disorders, cardiovascular diseases, neurological diseases, and other (hormonal disorders). Among the applications, the oncology sub-segment is anticipated to hold a considerable share of the market owing to the rise in the development of oncology drugs including a wide range of medications such as targeted therapies, chemotherapy agents, immunotherapies, and hormone therapies to treat cancer.

The Vaccines Sub-Segment is Anticipated to Hold a Considerable Share of the Global Biopharmaceuticals Market

Among the product types, the vaccines sub-segment is expected to hold a considerable share of the global biopharmaceutical market. The segmental growth is attributed to an increase in the integration of nanotechnology, gene-based assays, next-generation sequencing technologies, and genetic engineering in the process of vaccine development is expected to enhance the revolutionary potential of novel vaccine types. Nucleic acid vaccines, mRNA vaccines, vector vaccines, and biomaterial-based vaccines are recent trends in the revolutionization of vaccines based on their potential to address issues of existing technology. For instance, in September 2023, Pfizer Inc. and BioNTech SE announced that the US FDA approved the supplemental biologics license application for individuals 12 years and older and granted emergency use authorization for individuals 6 months through 11 years of age for the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine.

Regional Outlook

The global biopharmaceuticals market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to a strong base of healthcare facilities, and the availability of advanced treatment options that specifically target the underlying causes of these complex diseases, improved therapeutic outcomes, and enhanced patient care in this region.

The North American region is Expected to Grow at a Significant CAGR in the Global Biopharmaceuticals Market

Among all regions, the North American region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to a rise in the adoption and availability of biopharmaceuticals for disease treatment and a surge in disease diagnosis awareness. Demand for local and imported pharmaceutical products increased as economies grew, and healthcare provision and insurance mechanisms expanded. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in May 2022, in 2021 North America accounted for 49.1% of global pharmaceutical sales compared with 23.4% for Europe. the diversity of pharmaceutical needs as emerging markets increasingly address noncommunicable diseases (NCDs) already prevalent in stronger economies, including diabetes and hypertension, while communicable diseases that afflict many emerging markets such as acquired immunodeficiency syndrome, malaria, and tuberculosis persist. The increase in the global population is also contributing to pharmaceutical consumption.

The market growth is driven by various factors, such as an increase in the elderly population, a surge in the prevalence of chronic diseases such as cancer and diabetes, and an increase in the adoption of biopharmaceuticals globally. Furthermore, a rise in strategic collaborations among biopharmaceutical companies is also anticipated to supplement the growth of the biopharmaceutical industry. The key market player includes AbbVie Inc., AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co., Inc., Pfizer Inc. and others.

Market Players Outlook

The major companies serving the biopharmaceuticals market include F. Hoffmann-La Roche AG, Johnson & Johnson, AbbVie, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2020, IAVI, a nonprofit scientific research organization addressing urgent, unmet global health challenges, and Serum Institute of India Pvt. Ltd., a manufacturer of vaccines and biologics, announced an agreement with Merck KGaA, Darmstadt, Germany, a science and technology company, to develop COVID-19 neutralizing monoclonal antibodies (mAbs).

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global biopharmaceuticals market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. AbbVie, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Johnson and Johnson Service, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Pfizer, Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. F. Hoffman-La Roche, Ltd.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Biopharmaceuticals Market by Product Type
    • 4.1.1. Monoclonal Antibodies
    • 4.1.2. Recombinant Growth Factors
    • 4.1.3. Purified Proteins
    • 4.1.4. Vaccines
    • 4.1.5. Hormone
    • 4.1.6. Gene Therapies
    • 4.1.7. Other (Interferon, Synthetic Immunomodulators)
  • 4.2. Global Biopharmaceuticals Market by Service
    • 4.2.1. Laboratory Testing
    • 4.2.2. Customer Proprietary Testing
    • 4.2.3. Compendial and Multi Compendial Laboratory Testing
  • 4.3. Global Biopharmaceuticals Market by Application
    • 4.3.1. Oncology
    • 4.3.2. Inflammatory and Infectious Diseases
    • 4.3.3. Autoimmune Disorders
    • 4.3.4. Metabolic Disorders
    • 4.3.5. Cardiovascular Diseases
    • 4.3.6. Neurological Diseases
    • 4.3.7. Other(Hormonal Disorders)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East and Africa

6. Company Profiles

  • 6.1. AbbVie Inc.
  • 6.2. Bayer AG
  • 6.3. Abbott Laboratories
  • 6.4. Allergan, Inc.
  • 6.5. Amgen Inc.
  • 6.6. AstraZeneca plc
  • 6.7. Bayer AG
  • 6.8. Biogen Inc.
  • 6.9. bioMerieux SA
  • 6.10. Bristol-Myers Squibb
  • 6.11. Eli Lilly and Company
  • 6.12. GlaxoSmithKline PlcPharmaceuticals Ltd.
  • 6.13. McKesson Corp.
  • 6.14. Moderna, Inc.
  • 6.15. Merck & Co., Inc.
  • 6.16. Novartis AG
  • 6.17. Novo Nordisk A/S
  • 6.18. Sanofi SA
  • 6.19. Takeda Pharmaceutical Industries, Ltd.
  • 6.20. Vertex Pharmaceuticals